AIM
SCLN

Alambic Investment Management’s Sciclone Pharmaceuticals Inc SCLN Stock Holding History

Alambic Investment Management’s Portfolio SCLN Stock Details SCLN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2017
Q3 		– Sell
-24,300
Closed -$267K – 646
2017
Q2 		$267K Sell
24,300
-10,600
-30% -$106K 0.03% 476
2017
Q1 		$342K Buy
34,900
+21,900
+168% +$219K 0.04% 480
2016
Q4 		$140K Buy
+13,000
New +$130K 0.02% 526

Other funds holding SCLN

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
GP
GLG Partners London, United Kingdom $2.14B AUM 21.14% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
AQR Capital Management
AQR Capital Management Greenwich, Connecticut $218B AUM 29.41% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return
MWNA
Marshall Wace North America New York $23.5B AUM 46.46% 1-Year Est. Return
Bank of New York Mellon
Bank of New York Mellon New York $544B AUM 28.31% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

Alambic Investment Management's SCLN Position: Q3 2017 in Review

Alambic Investment Management sold out of Sciclone Pharmaceuticals Inc (SCLN) in Q3 2017, closing a stake of 24,300 shares — an estimated $267K sold.

Alambic Investment Management first reported a position in SCLN in Q4 2016 and held it in 3 quarters. The position peaked at $342K in Q1 2017. 129 funds tracked by Wall St. Rank hold SCLN as of Q3 2017.

  • Alambic Investment Management reported no remaining Sciclone Pharmaceuticals Inc position as of Q3 2017 after selling out during the quarter.
  • Alambic Investment Management sold 24,300 Sciclone Pharmaceuticals Inc shares in Q3 2017, an estimated $267K.
  • Alambic Investment Management first reported a position in Sciclone Pharmaceuticals Inc in Q4 2016 and held it in 3 quarters.
  • Alambic Investment Management's Sciclone Pharmaceuticals Inc position peaked at $342K in Q1 2017.
  • 129 funds tracked by Wall St. Rank held Sciclone Pharmaceuticals Inc as of Q3 2017.

Based on Alambic Investment Management's 13F filing for Q3 2017, filed 13 Nov 2017.